Human Papillomavirus and Head and Neck Cancer

  • Anil Chaturvedi
  • Maura L. Gillison

Abstract

Human papillomaviruses (HPV) have been implicated in the pathogenesis of several cancers of the anogenital tract, including cervical, vulvar, vaginal, and anal cancers in women and penile and anal cancers among men. In 2007, the World Health Organization stated for the first time that there was sufficient molecular and epidemiological evidence to conclude that HPVs are also etiologic for a nonanogenital malignancy, specifically oral cancers [1] . HPV infection is necessary for the development of cervical carcinoma, where HPV genomic DNA is identified in virtually all cancers (>99%) [2] . By contrast, for all other HPV-associated malignancies inclusive of oral cancers, only a subset of cancers at that anatomic site is attributable to HPV [3, 4] . Taken together, an estimated 561,000 men and women worldwide were diagnosed with cancers attributable to HPV infection in 2002 [5] , accounting for approximately 5.2% of the global cancer burden [6] . According to the Centers for Disease Control, approximately 20,000 cancers in the United States were attributable to HPV infection each year during the period from 1998 through 2003 [4, 7] . HPV infection is therefore a major cause of morbidity and mortality from cancers worldwide.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    International Agency for Research on Cancer (2007) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. vol 90: Human PapillomavirusesGoogle Scholar
  2. 2.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–9PubMedCrossRefGoogle Scholar
  3. 3.
    Gillison ML, Shah KV (2003) Chapter 9: role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr (31):57–65PubMedCrossRefGoogle Scholar
  4. 4.
    Gillison ML, Chaturvedi AK, Lowy DR (2008) HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113(10):3036–46PubMedCrossRefGoogle Scholar
  5. 5.
    Parkin DM, Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24(Suppl 3): S11–S25CrossRefGoogle Scholar
  6. 6.
    Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118(12):3030–44PubMedCrossRefGoogle Scholar
  7. 7.
    Watson M, Saraiya M, Ahmed F, Cardinez CJ, Reichman ME, Weir HK et al (2008) Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer 113(10 Suppl):2841–54PubMedCrossRefGoogle Scholar
  8. 8.
    Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L et al (2008) Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26(Suppl 10):K1–16PubMedCrossRefGoogle Scholar
  9. 9.
    Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S et al (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366(9490):991–8PubMedCrossRefGoogle Scholar
  10. 10.
    Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT et al (2006) Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 119(11):2677–84PubMedCrossRefGoogle Scholar
  11. 11.
    Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS et al (2007) Prevalence of HPV infection among females in the United States. JAMA 297(8):813–9PubMedCrossRefGoogle Scholar
  12. 12.
    Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR (2006) Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 194(8):1044–57PubMedCrossRefGoogle Scholar
  13. 13.
    Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi LF et al (2007) Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 196(8):1128–36PubMedCrossRefGoogle Scholar
  14. 14.
    De Koning MN, Struijk L, Bavinck JN, Kleter B, Ter SJ, Quint WG et al (2007) Betapapillomaviruses frequently persist in the skin of healthy individuals. J Gen Virol 88(Pt 5):1489–95PubMedCrossRefGoogle Scholar
  15. 15.
    Weissenborn SJ, De Koning MN, Wieland U, Quint WG, Pfister HJ (2009) Intrafamilial transmission and family-specific spectra of cutaneous betapapillomaviruses. J Virol 83(2):811–6PubMedCrossRefGoogle Scholar
  16. 16.
    Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP et al (1993) The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol 67(11):6413–23PubMedGoogle Scholar
  17. 17.
    Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromara-Nazos P, Labropoulou V et al (1993) Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 67(11):6424–31PubMedGoogle Scholar
  18. 18.
    Stubenrauch F, Laimins LA (1999) Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol 9(6):379–86PubMedCrossRefGoogle Scholar
  19. 19.
    Wang XM, Jansen KU, McClements WL (2003) DNA replicative functions of highly-expressed, codon-optimized human papillomavirus proteins E1 and E2. J Virol Methods 108(1):83–90PubMedCrossRefGoogle Scholar
  20. 20.
    Wilson VG, West M, Woytek K, Rangasamy D (2002) Papillomavirus E1 proteins: form, function, and features. Virus Genes 24(3):275–90PubMedCrossRefGoogle Scholar
  21. 21.
    Soeda E, Ferran MC, Baker CC, McBride AA (2006) Repression of HPV16 early region transcription by the E2 protein. Virology 351(1):29–41PubMedCrossRefGoogle Scholar
  22. 22.
    Wilson R, Ryan GB, Knight GL, Laimins LA, Roberts S (2007) The full-length E1E4 protein of human papillomavirus type 18 modulates differentiation-dependent viral DNA amplification and late gene expression. Virology 362(2):453–60PubMedCrossRefGoogle Scholar
  23. 23.
    Genther Williams SM, Disbrow GL, Schlegel R, Lee D, Threadgill DW, Lambert PF (2005) Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res 65(15):6534–42CrossRefGoogle Scholar
  24. 24.
    Tsai TC, Chen SL (2003) The biochemical and biological functions of human papillomavirus type 16 E5 protein. Arch Virol 148(8):1445–53PubMedCrossRefGoogle Scholar
  25. 25.
    Ashrafi GH, Brown DR, Fife KH, Campo MS (2006) Down-regulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res 120(1–2):208–11PubMedCrossRefGoogle Scholar
  26. 26.
    Munger K, Howley PM (2002) Human papillomavirus immortalization and transformation functions. Virus Res 89(2):213–28PubMedCrossRefGoogle Scholar
  27. 27.
    Mantovani F, Banks L (2001) The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20(54):7874–87PubMedCrossRefGoogle Scholar
  28. 28.
    Klingelhutz AJ, Foster SA, McDougall JK (1996) Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380(6569):79–82PubMedCrossRefGoogle Scholar
  29. 29.
    Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M et al (2001) Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20(54):7888–98PubMedCrossRefGoogle Scholar
  30. 30.
    Romanczuk H, Howley PM (1992) Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci U S A 89(7):3159–63PubMedCrossRefGoogle Scholar
  31. 31.
    Gissmann L, zur Hausen H (1980) Partial characterization of viral DNA from human genital warts (Condylomata acuminata). Int J Cancer 25(5):605–9PubMedCrossRefGoogle Scholar
  32. 32.
    zur Hausen H (2009) Papillomaviruses in the causation of human cancers – a brief historical account. Virology 384:260–265CrossRefGoogle Scholar
  33. 33.
    Durst M, Gissmann L, Ikenberg H, zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 80(12):3812–5PubMedCrossRefGoogle Scholar
  34. 34.
    de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324(1):17–27CrossRefGoogle Scholar
  35. 35.
    Schlegel R, Phelps WC, Zhang YL, Barbosa M (1988) Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J 7(10):3181–7PubMedGoogle Scholar
  36. 36.
    Storey A, Pim D, Murray A, Osborn K, Banks L, Crawford L (1988) Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J 7(6):1815–20PubMedGoogle Scholar
  37. 37.
    Phelps WC, Yee CL, Munger K, Howley PM (1988) The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53(4):539–47PubMedCrossRefGoogle Scholar
  38. 38.
    Hiller T, Poppelreuther S, Stubenrauch F, Iftner T (2006) Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev 15(7):1262–7PubMedCrossRefGoogle Scholar
  39. 39.
    Heck DV, Yee CL, Howley PM, Munger K (1992) Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 89(10):4442–6PubMedCrossRefGoogle Scholar
  40. 40.
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6):518–27PubMedCrossRefGoogle Scholar
  41. 41.
    Munoz N, Castellsague X, de Gonzalez AB, Gissmann L (2006) Chapter 1: HPV in the etiology of human cancer. Vaccine 24(Suppl 3):S31–S310Google Scholar
  42. 42.
    Gillison ML (2004) Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31(6):744–54PubMedCrossRefGoogle Scholar
  43. 43.
    Syrjanen S (2005) Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 32(Suppl 1):S59–S66PubMedCrossRefGoogle Scholar
  44. 44.
    Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14(2):467–75PubMedCrossRefGoogle Scholar
  45. 45.
    Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92(9):709–20PubMedCrossRefGoogle Scholar
  46. 46.
    Ragin CC, Reshmi SC, Gollin SM (2004) Mapping and analysis of HPV16 integration sites in a head and neck cancer cell line. Int J Cancer 110(5):701–9PubMedCrossRefGoogle Scholar
  47. 47.
    Begum S, Cao D, Gillison M, Zahurak M, Westra WH (2005) Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 11(16):5694–9PubMedCrossRefGoogle Scholar
  48. 48.
    van Houten V, Snijders PJ, van den Brekel MW, Kummer JA, Meijer CJ, van Leeuwen B et al (2001) Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 93(2):232–5PubMedCrossRefGoogle Scholar
  49. 49.
    Koskinen WJ, Chen RW, Leivo I, Makitie A, Back L, Kontio R et al (2003) Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer 107(3):401–6PubMedCrossRefGoogle Scholar
  50. 50.
    Kreimer AR, Clifford GM, Snijders PJ, Castellsague X, Meijer CJ, Pawlita M et al (2005) HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. Int J Cancer 115(2):329–32PubMedCrossRefGoogle Scholar
  51. 51.
    Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, Rabbani H, Kalantari M et al (2002) Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 102(2):152–8PubMedCrossRefGoogle Scholar
  52. 52.
    Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M et al (2001) Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92(11):2875–84PubMedCrossRefGoogle Scholar
  53. 53.
    Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR et al (2004) Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 96(13):998–1006PubMedCrossRefGoogle Scholar
  54. 54.
    Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H (2003) Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2–11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63(6):1188–91PubMedGoogle Scholar
  55. 55.
    Zumbach K, Hoffmann M, Kahn T, Bosch F, Gottschlich S, Gorogh T et al (2000) Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma. Int J Cancer 85(6):815–8PubMedCrossRefGoogle Scholar
  56. 56.
    Hoffmann TK, Arsov C, Schirlau K, Bas M, Friebe-Hoffmann U, Klussmann JP et al (2006) T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 118(8):1984–91PubMedCrossRefGoogle Scholar
  57. 57.
    Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C et al (2005) Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65(23):11146–55PubMedCrossRefGoogle Scholar
  58. 58.
    Dai M, Clifford GM, le Calvez F, Castellsague X, Snijders PJ, Pawlita M et al (2004) Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res 64(2):468–71PubMedCrossRefGoogle Scholar
  59. 59.
    Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R et al (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24(36):5630–6PubMedCrossRefGoogle Scholar
  60. 60.
    Fakhry C, Gillison ML (2006) Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24(17):2606–11PubMedCrossRefGoogle Scholar
  61. 61.
    Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH et al (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26(19):3128–37PubMedCrossRefGoogle Scholar
  62. 62.
    Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J et al (2006) Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24(5):736–47PubMedCrossRefGoogle Scholar
  63. 63.
    Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X et al (2006) Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 12(3 Pt 1):701–9PubMedCrossRefGoogle Scholar
  64. 64.
    Schlecht NF, Burk RD, Adrien L, Dunne A, Kawachi N, Sarta C et al (2007) Gene expression profiles in HPV-infected head and neck cancer. J Pathol 213(3):283–93PubMedCrossRefGoogle Scholar
  65. 65.
    Carter JJ, Galloway DA (1997) Humoral immune response to human papillomavirus infection. Clin Dermatol 15(2):249–59PubMedCrossRefGoogle Scholar
  66. 66.
    Meschede W, Zumbach K, Braspenning J, Scheffner M (1998) itez-Bribiesca L, Luande J et al. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 36(2):475–80Google Scholar
  67. 67.
    Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P et al (2003) Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95(23):1772–83PubMedCrossRefGoogle Scholar
  68. 68.
    Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM et al (1998) Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90(21):1626–36PubMedCrossRefGoogle Scholar
  69. 69.
    Smith EM, Ritchie JM, Summersgill KF, Hoffman HT, Wang DH, Haugen TH et al (2004) Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 96(6):449–55PubMedCrossRefGoogle Scholar
  70. 70.
    Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S et al (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100(6):407–20PubMedCrossRefGoogle Scholar
  71. 71.
    Furniss CS, McClean MD, Smith JF, Bryan J, Nelson HH, Peters ES et al (2007) Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer 120(11):2386–92PubMedCrossRefGoogle Scholar
  72. 72.
    Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P et al (2001) Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344(15):1125–31PubMedCrossRefGoogle Scholar
  73. 73.
    Dahlstrom KR, Adler-Storthz K, Etzel CJ, Liu Z, Dillon L, El Naggar AK et al (2003) Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in neversmokers: a matched pair analysis. Clin Cancer Res 9(7):2620–6PubMedGoogle Scholar
  74. 74.
    Smith EM, Ritchie JM, Pawlita M, Rubenstein LM, Haugen TH, Turek LP et al (2007) Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer 120(4):825–32PubMedCrossRefGoogle Scholar
  75. 75.
    D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM et al (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356(19):1944–56PubMedCrossRefGoogle Scholar
  76. 76.
    Pintos J, Black MJ, Sadeghi N, Ghadirian P, Zeitouni AG, Viscidi RP et al (2008) Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol 44(3):242–50PubMedCrossRefGoogle Scholar
  77. 77.
    Smith EM, Summersgill KF, Allen J, Hoffman HT, McCulloch T, Turek LP et al (2000) Human papillomavirus and risk of laryngeal cancer. Ann Otol Rhinol Laryngol 109(11):1069–76PubMedGoogle Scholar
  78. 78.
    Strome SE, Savva A, Brissett AE, Gostout BS, Lewis J, Clayton AC et al (2002) Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res 8(4):1093–100PubMedGoogle Scholar
  79. 79.
    Hansson BG, Rosenquist K, Antonsson A, Wennerberg J, Schildt EB, Bladstrom A et al (2005) Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol 125(12):1337–44PubMedCrossRefGoogle Scholar
  80. 80.
    Trottier H, Franco EL (2006) The epidemiology of genital human papillomavirus infection. Vaccine 24(Suppl 1):S1–15PubMedGoogle Scholar
  81. 81.
    Maden C, Beckmann AM, Thomas DB, McKnight B, Sherman KJ, Ashley RL et al (1992) Human papillomaviruses, herpes simplex viruses, and the risk of oral cancer in men. Am J Epidemiol 135(10):1093–102PubMedGoogle Scholar
  82. 82.
    Koch WM, Lango M, Sewell D, Zahurak M, Sidransky D (1999) Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope 109(10):1544–51PubMedCrossRefGoogle Scholar
  83. 83.
    Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT (2002) Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 8(10):3187–92PubMedGoogle Scholar
  84. 84.
    Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM (2001) Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92(4):805–13PubMedCrossRefGoogle Scholar
  85. 85.
    Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D et al (1996) Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 2(4):755–62PubMedGoogle Scholar
  86. 86.
    Applebaum KM, Furniss CS, Zeka A, Posner MR, Smith JF, Bryan J et al (2007) Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 99(23):1801–10PubMedCrossRefGoogle Scholar
  87. 87.
    Wiley DJ, Wiesmeier E, Masongsong E, Gylys KH, Koutsky LA, Ferris DG et al (2006) Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection. Cancer Epidemiol Biomarkers Prev 15(5):915–20PubMedCrossRefGoogle Scholar
  88. 88.
    Meyer MS, Applebaum KM, Furniss CS, Peters ES, Luckett BG, Smith JF et al (2008) Human papillomavirus-16 modifies the association between fruit consumption and head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 17(12):3419–26PubMedCrossRefGoogle Scholar
  89. 89.
    AB Hill (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300Google Scholar
  90. 90.
    Rampias T, Sasaki C, DiMaio D, Psyrri A (2007) Retrovirus-mediated delivery of short hairpin RNA targeting human papillomavirus (HPV) 16 E6 and E7 oncogenes and induction of apoptosis in oropharyngeal squamous cell cancer (OSCC) cell line. J Clin Oncol (Meeting Abstracts) 25(18 Suppl):6002Google Scholar
  91. 91.
    Smith EM, Ritchie JM, Yankowitz J, Swarnavel S, Wang D, Haugen TH et al (2004) Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission. Sex Transm Dis 31(1):57–62PubMedCrossRefGoogle Scholar
  92. 92.
    D’Souza G, Fakhry C, Sugar EA, Seaberg EC, Weber K, Minkoff HL et al (2007) Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 121:143–150PubMedCrossRefGoogle Scholar
  93. 93.
    Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Garrett ES et al (2004) Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 189(4):686–98PubMedCrossRefGoogle Scholar
  94. 94.
    Rintala MA, Grenman SE, Puranen MH, Isolauri E, Ekblad U, Kero PO et al (2005) Transmission of high-risk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland. J Clin Microbiol 43(1):376–81PubMedCrossRefGoogle Scholar
  95. 95.
    Cameron JE, Mercante D, O’Brien M, Gaffga AM, Leigh JE, Fidel PL Jr et al (2005) The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults. Sex Transm Dis 32(11):703–9PubMedCrossRefGoogle Scholar
  96. 96.
    Fakhry C, D’Souza G, Sugar E, Weber K, Goshu E, Minkoff H et al (2006) Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol 44(12):4479–85PubMedCrossRefGoogle Scholar
  97. 97.
    Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM et al (2005) Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191(5):731–8PubMedCrossRefGoogle Scholar
  98. 98.
    Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G et al (2004) Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis 190(12):2070–6PubMedCrossRefGoogle Scholar
  99. 99.
    Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee JH et al (2008) Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 198(6):827–35PubMedCrossRefGoogle Scholar
  100. 100.
    Chin-Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, Colfax G et al (2005) Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst 97(12):896–905PubMedCrossRefGoogle Scholar
  101. 101.
    Rintala M, Grenman S, Puranen M, Syrjanen S (2006) Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPV Family Study. J Clin Virol 35(1):89–94PubMedCrossRefGoogle Scholar
  102. 102.
    Schlecht NF, Burk RD, Palefsky JM, Minkoff H, Xue X, Massad LS et al (2005) Variants of human papillomaviruses 16 and 18 and their natural history in human immunodeficiency virus-positive women. J Gen Virol 86(Pt 10):2709–20PubMedCrossRefGoogle Scholar
  103. 103.
    Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM et al (2008) Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 26(19):3138–46PubMedCrossRefGoogle Scholar
  104. 104.
    Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100(4):261–9PubMedCrossRefGoogle Scholar
  105. 105.
    Dahlgren L, Dahlstrand HM, Lindquist D, Hogmo A, Bjornestal L, Lindholm J et al (2004) Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients. Int J Cancer 112(6):1015–9PubMedCrossRefGoogle Scholar
  106. 106.
    Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, Preuss SF, Hoffmann TK et al (2007) Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120(8):1731–8PubMedCrossRefGoogle Scholar
  107. 107.
    Hafkamp HC, Manni JJ, Haesevoets A, Voogd AC, Schepers M, Bot FJ et al (2008) Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 122(12):2656–64PubMedCrossRefGoogle Scholar
  108. 108.
    Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA et al (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357(25):2552–61PubMedCrossRefGoogle Scholar
  109. 109.
    Smith EM, Wang D, Rubenstein LM, Morris WA, Turek LP, Haugen TH (2008) Association between p53 and human papillomavirus in head and neck cancer survival. Cancer Epidemiol Biomarkers Prev 17(2):421–7PubMedCrossRefGoogle Scholar
  110. 110.
    Chaturvedi AK, Engels EA, Anderson WF, Gillison ML (2008) Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26(4):612–9PubMedCrossRefGoogle Scholar
  111. 111.
    Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP (2005) Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114(5):806–16PubMedCrossRefGoogle Scholar
  112. 112.
    Sturgis EM, Cinciripini PM (2007) Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 110(7):1429–35PubMedCrossRefGoogle Scholar
  113. 113.
    Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ (2000) Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 11(6):489–95PubMedCrossRefGoogle Scholar
  114. 114.
    Shiboski CH, Shiboski SC, Silverman S Jr (2000) Trends in oral cancer rates in the United States, 1973–1996. Community Dent Oral Epidemiol 28(4):249–56PubMedCrossRefGoogle Scholar
  115. 115.
    Shiboski CH, Schmidt BL, Jordan RC (2005) Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer 103(9):1843–9Google Scholar
  116. 116.
    Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J et al (2006) Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 119(11):2620–3PubMedCrossRefGoogle Scholar
  117. 117.
    Frisch M, Biggar RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92(18):1500–10PubMedCrossRefGoogle Scholar
  118. 118.
    Chaturvedi AK, Engels EA, Gilbert ES, Chen BE, Storm H, Lynch CF et al (2007) Second cancers among 104, 760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 99(21):1634–43PubMedCrossRefGoogle Scholar
  119. 119.
    Hemminki K, Dong C, Frisch M (2000) Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur J Cancer Prev 9(6):433–7PubMedCrossRefGoogle Scholar
  120. 120.
    Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369(9580): 2161–70PubMedCrossRefGoogle Scholar
  121. 121.
    Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928–43PubMedCrossRefGoogle Scholar
  122. 122.
    FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19):1915–27.Google Scholar
  123. 123.
    Schiller JT, Lowy DR (2006) Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res 66(21):10229–32PubMedCrossRefGoogle Scholar
  124. 124.
    Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC et al (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298(7):743–53PubMedCrossRefGoogle Scholar
  125. 125.
    Petaja T, Keranen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M et al (2009) Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years. J Adolesc Health 44(1):33–40PubMedCrossRefGoogle Scholar
  126. 126.
    Gillison ML (2008) Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination GILLISON2008A. J Adolesc Health 43 (4 Suppl):S52–S60PubMedCrossRefGoogle Scholar
  127. 127.
    Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA et al (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 92(25):11553–7PubMedCrossRefGoogle Scholar
  128. 128.
    Cameron JE, Snowhite IV, Chaturvedi AK, Hagensee ME (2003) Human papillomavirusspecific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals. Clin Diagn Lab Immunol 10(3):431–8PubMedGoogle Scholar
  129. 129.
    Buchinsky FJ, Carter JJ, Wipf GC, Hughes JP, Koutsky LA, Galloway DA (2006) Comparison of oral fluid and serum ELISAs in the determination of IgG response to natural human papillomavirus infection in university women. J Clin Virol 35(4):450–3PubMedCrossRefGoogle Scholar
  130. 130.
    Kemp TJ, Garcia-Pineres A, Falk RT, Poncelet S, Dessy F, Giannini SL et al (2008) Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 26(29–30):3608–16PubMedCrossRefGoogle Scholar
  131. 131.
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (2007) Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56(RR-2):1–24PubMedGoogle Scholar
  132. 132.
    Giuliano AR, Salmon D (2008) The case for a gender-neutral (universal) human papillomavirus vaccination policy in the United States: Point. Cancer Epidemiol Biomarkers Prev 17(4):805–8PubMedCrossRefGoogle Scholar
  133. 133.
    Canadas MP, Bosch FX, Junquera ML, Ejarque M, Font R, Ordonez E et al (2004) Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population. J Clin Microbiol 42(3):1330–2PubMedCrossRefGoogle Scholar
  134. 134.
    do Sacramento PR, Babeto E, Colombo J, Cabral Ruback MJ, Bonilha JL, Fernandes AM et al (2006) The prevalence of human papillomavirus in the oropharynx in healthy individuals in a Brazilian population. J Med Virol 78(5):614–8PubMedCrossRefGoogle Scholar
  135. 135.
    Marais DJ, Passmore JA, Denny L, Sampson C, Allan BR, Williamson AL (2008) Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa. J Med Virol 80(6):953–9PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Anil Chaturvedi
  • Maura L. Gillison

There are no affiliations available

Personalised recommendations